EP Plenary session - Joint debate on Patents

Patentai ir augalų veislių selekcininkų teisinė apsauga (diskusijos)

Patents and plant breeders rights (debate)

Bendros patentinės apsaugos kūrimas - Bendra patentinė apsauga - Ginčų dėl patentų nagrinėjimo jurisdikcijos sistema (diskusijos)

Creation of unitary patent protection - Unitary patent protection - Jurisdictional system for patent disputes (debate)

Esminių biologinių procesų patentavimas (diskusijos)

Patenting of essential biological processes (debate)

Workshop - Policy Departements and Administration : Stem cell Research and patenting

ENVI

Tvirtesnis bendradarbiavimas kuriant bendrą patentinę apsaugą (diskusijos)

Enhanced cooperation in the area of the creation of unitary patent protection (debate)

JURI committee meeting. Exchange of views with Romanian Presidency. Presentation of study on Essential Patents and Internet of Things, commissioned by the European Parliament's Policy Department for Citizens' Rights and Constitutional Affairs at the request of JURI committee

Public Hearing - The Unitary patent : state of play in the context of Brexit

PAPADIMOULIS, Dimitrios (GUE/NGL, GR) - EP Vice-President

Plenary session week 51 2015 in Strasbourg - Patents and plant breeders rights - Oral question

Green meeting about patenting food and GMOs

JURI committee Hearing on Patent

Andreas MAVROYIANNIS, Raffaele BALDASSARRE, Martin SCHULZ - EP President

Lex Signing: European Unitary Patent Package

Plenary session week 50 -2012  in Strasbourg - European Patent

Press conference on the campaign against the patenting of biotechnical discoveries - No Patents on Life - with Nobel Prize for Literature winner Dario FO.

Martin SCHULZ - EP President, Evelyne GEBHARDT

Evelyne GEBHARDT and  M. THEN from No patents on Seeds Hand over a letter to Martin SCHULZ EP-President

Carl SCHLYTER, Raul ROMEVA I RUEDA, Elisabeth SCHROEDTER, Isabelle DURANT, Jose BOVE, Franziska BRANTNER, Martin HAUSLING, Jean-Paul BESSET, Nikos CHRYSOGELOS, Ulrike LUNACEK, Franziska KELLER

Greens / EFA group members stage a protest against patents in the agriculture sector

JURI Committee Meeting - Enhanced cooperation in the area of the creation of unitary patent protection with regard to the applicable translation arrangements

Illustration on the EU Patent at the Belgian Intellectual Property Office.

Press Conference on Biotechnical patents by: Eva LICHTENBERGER (Greens/EFA, AT) - Vittorio PRODI (S&D, IT) - Peter LIESE (EPP, DE)  - Miroslav MIKOLJIK (EPP, SL) - Carlo CASINI (EPP, IT)

Press conference in Strasbourg  : TRIPS and access to medicines - TRIPS : The EP was due to vote on whether to grant its assent to amending the TRIPS agreement to enable developing countries to make or import generic substitutes for patented medicines

Conference in Brussels on the European Patients' Rights day

No Software Patents demonstration at the EP in Strasbourg.

No Software Patents demonstration by the GreensEFA.

Intellectual property lies at the heart of innovation and competitiveness around the world as well as in the European Union. Intellectual property rights are protected mainly through patents, trademarks and copyright. They enable individuals and companies to earn recognition and/or financial benefit from what they invent or create. By striking the right balance between innovators and public interest, intellectual property aims to foster an environment in which creativity and innovation can flourish. But despite impressive patent activity, European businesses still encounter various challenges to register or protect patents. Restrictions: ©The material may not be edited and must be shown entirely.

EPRS - Key challenges for European patents

Parlamentas diskutavo, ar nereikėtų atsisakyti vakcinų nuo COVID-19 patentų, ir pritarė įtraukesnei „Erasmus +“ programai. Į darbotvarkę buvo įtraukti ir klimato klausimai: Europarlamentarai patvirtino Teisingos pertvarkos fondą, kuris padėtų regionams lengviau pereiti prie ekologiškesnės ekonomikos, bei paragino ES labiau stengtis apsaugoti aplinkos aktyvistus. Parlamento nariai taip pat aptarė Izraelio ir Palestinos konflikto eskalavimą.

Svarbiausi plenarinio posėdžio klausimai: vakcinų nuo COVID-19 patentai, programa „Erasmus +“ ir aplinkos aktyvistai

During the plenary session of the European Parliament in Brussels (17-20 May 2021), MEPs debate proposal to the WTO to waive intellectual property rights for COVID-19 vaccines, a move backed by the US administration. Extracts from the debate: statements by Augusto SANTOS SILVA, Portuguese Minister of State for Foreign Affairs, Valdis DOMBROVSKIS, Executive Vice-President of the EC in charge of an Economy that works for People, Esther de LANGE (EPP, NL), Iratxe GARCÍA PÉREZ (S&D, ES), Dacian CIOLOŞ (Renew, RO), Tilly METZ (Greens/EFA, LU), Marc BOTENGA (The Left, BE), and Gilles LEBRETON (ID, FR).

Waiver of the Global Covid 19 vaccines patents: extracts from the debate

During the plenary session of the European Parliament in Brussels (17-20 May 2021), MEPs debate on the meeting the Global COVID-19 challenge: effects of waiver of the WTO TRIPS agreement on COVID-19 vaccines, treatment, equipment and manufacturing capacity in developing countries: Closing statements by Valdis DOMBROVSKIS, Executive Vice-President of the European Commission in charge of an Economy that works for People, and Commissioner for Trade and by Augusto SANTOS SILVA, Portuguese Minister of State for Foreign Affairs

Meeting the Global COVID-19 challenge: effects of waiver of the WTO TRIPS agreement on COVID-19 vaccines, treatment, equipment and manufacturing capacity in developing countries: Closing statements by Council and Comission

During the plenary session of the European Parliament in Brussels (17-20 May 2021), MEPs debate on the meeting the Global COVID-19 challenge: effects of waiver of the WTO TRIPS agreement on COVID-19 vaccines, treatment, equipment and manufacturing capacity in developing countries: MEPs debate part 1/3

Meeting the Global COVID-19 challenge: effects of waiver of the WTO TRIPS agreement on COVID-19 vaccines, treatment, equipment and manufacturing capacity in developing countries: MEPs debate part 1/3

During the plenary session of the European Parliament in Brussels (17-20 May 2021), MEPs debate on the meeting the Global COVID-19 challenge: effects of waiver of the WTO TRIPS agreement on COVID-19 vaccines, treatment, equipment and manufacturing capacity in developing countries: MEPs debate part 3/3

Meeting the Global COVID-19 challenge: effects of waiver of the WTO TRIPS agreement on COVID-19 vaccines, treatment, equipment and manufacturing capacity in developing countries: MEPs debate part 3/3

During the plenary session of the European Parliament in Brussels (17-20 May 2021), MEPs debate on the meeting the Global COVID-19 challenge: effects of waiver of the WTO TRIPS agreement on COVID-19 vaccines, treatment, equipment and manufacturing capacity in developing countries: MEPs debate part 2/3

Meeting the Global COVID-19 challenge: effects of waiver of the WTO TRIPS agreement on COVID-19 vaccines, treatment, equipment and manufacturing capacity in developing countries: MEPs debate part 2/3

During the plenary session of the European Parliament in Brussels (17-20 May 2021), MEPs debate on the meeting the Global COVID-19 challenge: effects of waiver of the WTO TRIPS agreement on COVID-19 vaccines, treatment, equipment and manufacturing capacity in developing countries: Opening statements by Augusto SANTOS SILVA, Portuguese Minister of State for Foreign Affairs and by Valdis DOMBROVSKIS, Executive Vice-President of the European Commission in charge of an Economy that works for People, and Commissioner for Trade.

Meeting the Global COVID-19 challenge: effects of waiver of the WTO TRIPS agreement on COVID-19 vaccines, treatment, equipment and manufacturing capacity in developing countries: Opening statements Council and Commission

Europos Parlamentas pakartojo raginimą leisti nevaržomai naudotis augalų veisimo medžiaga. Parlamentarai nori užtikrinti, kad ūkininkai visoje ES galėtų diegti naujoves, siekdami kovoti su naujomis augalų ligomis ir klimato krizės padariniais. Turtingoms tarptautinėms įmonėms neturėtų būti leidžiama patentuoti natūralios gyvybės, taip kuriant monopolijas ir didinant maisto produktų kainas.

Natūraliai išvesti augalai ir jų sėklos neturėtų būti patentuojami

Paskutinis bendro ES patento kūrimo etapas reikalauja daug pastangų, bet paprastesnė sistema sumažins patentų kainą, siekiančią iki 36 000 eurų.

Išradimų patentavimo kainos mažinimas

Bendras ES patentas bus labai naudingas ES verslui, pasak Raffaele Baldassarre. Sophia in 't Veld įvardina pagrindinių teisių pažeidėjus Europoje.

7 dienos: Kova už pagrindines teises ir ES patentas

Po 30 metų derybų gal bus priimtas ES patentas. Kalbame su EP nariais Bernhard Rapkay iš Vokietijos ir Antonio Masip Hidalgo iš Ispanijos.

Nuomonės: ES patentas, paskutinis žingsnis?

EP stengiasi priimti ES patentą, abejonės valstybių narių sąžiningumu, pagalba Ispanijos bankams, ūkininkai reikalauja geresnių pieno supirkimo kainų.

ES patentas / CŽV skrydžiai / Ispanija / Pienas

EP nariai turi ramiai pažvelgti į bendro Europos patento ateitį po vienašališkai Tarybos priimtų ir audrą sukėlusių sutarto teksto pakeitimų.

Patentų problemos

Jis kainuoja 2000 eurų JAV ir iki 40 000 eurų Europoje. Bendras ES patentas bus pigesnis, bet jo įvedimas yra sudėtingas.

Reportažai: Išradimo patentavimas visame žemyne

Išradimų apsauga visoje ES greitai bus pigesnė, bet dar nesusitarta dėl detalių. Ir kitos dienos naujienos.

Naujienos: ES patentas

Išradimų apsauga visoje ES greitai bus pigesnė, bet dar nesusitarta dėl detalių.

25 ES šalys ėmėsi Europos patento reformos per bendradarbiavimą. Ar tai Europos bendruomenės pabaiga, ar mūsų konkurencingumo skatinimas?

20 rezultatai

EPRS - Key challenges for European patents

Svarbiausi plenarinio posėdžio klausimai: vakcinų nuo COVID-19 patentai, programa „Erasmus +“ ir aplinkos aktyvistai

Waiver of the Global Covid 19 vaccines patents: extracts from the debate

Meeting the Global COVID-19 challenge: effects of waiver of the WTO TRIPS agreement on COVID-19 vaccines, treatment, equipment and manufacturing capacity in developing countries: Closing statements by Council and Comission

Meeting the Global COVID-19 challenge: effects of waiver of the WTO TRIPS agreement on COVID-19 vaccines, treatment, equipment and manufacturing capacity in developing countries: MEPs debate part 1/3

Meeting the Global COVID-19 challenge: effects of waiver of the WTO TRIPS agreement on COVID-19 vaccines, treatment, equipment and manufacturing capacity in developing countries: MEPs debate part 3/3

Meeting the Global COVID-19 challenge: effects of waiver of the WTO TRIPS agreement on COVID-19 vaccines, treatment, equipment and manufacturing capacity in developing countries: MEPs debate part 2/3

Meeting the Global COVID-19 challenge: effects of waiver of the WTO TRIPS agreement on COVID-19 vaccines, treatment, equipment and manufacturing capacity in developing countries: Opening statements Council and Commission

Natūraliai išvesti augalai ir jų sėklos neturėtų būti patentuojami

Išradimų patentavimo kainos mažinimas

7 dienos: Kova už pagrindines teises ir ES patentas

Nuomonės: ES patentas, paskutinis žingsnis?

ES patentas / CŽV skrydžiai / Ispanija / Pienas

Patentų problemos

Reportažai: Išradimo patentavimas visame žemyne

Naujienos: ES patentas

Naujienos: ES patentas

Pro objektyvą: Europos patentas